Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by Blue Zone Wealth Advisors LLC

Blue Zone Wealth Advisors LLC boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,901 shares of the medical research company’s stock after buying an additional 436 shares during the quarter. Thermo Fisher Scientific accounts for 1.9% of Blue Zone Wealth Advisors LLC’s investment portfolio, making the stock its 19th largest position. Blue Zone Wealth Advisors LLC’s holdings in Thermo Fisher Scientific were worth $6,125,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in TMO. Axiom Advisory LLC raised its holdings in shares of Thermo Fisher Scientific by 1.6% in the third quarter. Axiom Advisory LLC now owns 1,216 shares of the medical research company’s stock valued at $720,000 after buying an additional 19 shares during the last quarter. Callan Family Office LLC increased its position in shares of Thermo Fisher Scientific by 21.0% in the third quarter. Callan Family Office LLC now owns 5,022 shares of the medical research company’s stock valued at $3,106,000 after buying an additional 871 shares in the last quarter. Aprio Wealth Management LLC boosted its stake in shares of Thermo Fisher Scientific by 9.5% during the third quarter. Aprio Wealth Management LLC now owns 867 shares of the medical research company’s stock valued at $536,000 after acquiring an additional 75 shares during the last quarter. Versant Capital Management Inc grew its position in shares of Thermo Fisher Scientific by 15.2% in the third quarter. Versant Capital Management Inc now owns 500 shares of the medical research company’s stock valued at $309,000 after purchasing an additional 66 shares during the period. Finally, Atwood & Palmer Inc. grew its stake in shares of Thermo Fisher Scientific by 0.5% during the 3rd quarter. Atwood & Palmer Inc. now owns 54,557 shares of the medical research company’s stock valued at $33,747,000 after buying an additional 268 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $598.85 on Tuesday. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $228.59 billion, a price-to-earnings ratio of 38.41, a P/E/G ratio of 3.88 and a beta of 0.77. The firm’s 50 day simple moving average is $609.46 and its 200 day simple moving average is $582.80. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, topping the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The firm had revenue of $10.54 billion for the quarter, compared to the consensus estimate of $10.50 billion. During the same period in the previous year, the business earned $5.15 EPS. The business’s quarterly revenue was down 1.4% compared to the same quarter last year. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Friday, September 13th will be given a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 0.26%. The ex-dividend date is Friday, September 13th. Thermo Fisher Scientific’s payout ratio is 10.01%.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at approximately $76,420,473.36. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $600.85, for a total transaction of $180,255.00. Following the completion of the transaction, the executive vice president now directly owns 17,887 shares in the company, valued at $10,747,403.95. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total value of $6,172,100.00. Following the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $76,420,473.36. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 23,084 shares of company stock worth $14,094,292. Insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on TMO. Stifel Nicolaus increased their price target on Thermo Fisher Scientific from $615.00 to $680.00 and gave the company a “buy” rating in a report on Friday, September 20th. Royal Bank of Canada reiterated an “outperform” rating and set a $767.00 price objective on shares of Thermo Fisher Scientific in a research note on Friday, September 20th. JPMorgan Chase & Co. increased their price objective on shares of Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an “overweight” rating in a research note on Friday, September 20th. Wells Fargo & Company initiated coverage on Thermo Fisher Scientific in a report on Tuesday, August 27th. They issued an “overweight” rating and a $670.00 price objective for the company. Finally, Bank of America increased their target price on Thermo Fisher Scientific from $600.00 to $675.00 and gave the stock a “buy” rating in a report on Monday, September 16th. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $653.72.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.